|

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

RECRUITINGPhase 1Sponsored by Nuvectis Pharma, Inc.
Actively Recruiting
PhasePhase 1
SponsorNuvectis Pharma, Inc.
Started2025-12-18
Est. completion2026-12
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations3 sites
View on ClinicalTrials.gov →

NCT07315113

Summary

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Provide written informed consent.
2. 18 years old or older.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
4. Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
5. Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.

Exclusion Criteria:

1. Subject's cancer has a known oncogenic driver alteration other than EGFR.
2. Known EGFR mutations that cause resistance to osimertinib
3. Known human epidermal growth factor receptor 2 (HER2) overexpression
4. Any contraindications to treatment with osimertinib

Conditions4

CancerEGFR Mutated Non-small Cell Lung Cancer PatientsEGFR Mutation Positive Non-small Cell Lung CancerLung Cancer

Locations3 sites

Massachusetts

1 site
Massachusetts General Hospital
Boston, Massachusetts, 02114

Texas

1 site
NEXT Houston
Houston, Texas, 77054

Virginia

1 site
NEXT Virginia
Fairfax, Virginia, 22031

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.